http://www.fiercepharma.com/story/st...oys/2009-06-25
Short, interesting discussion of the cost factors for Merck in the link.
Quote:
| Merck's quest to expand the use of Gardasil to boys may have hit a snag. A new study by Harvard researchers found that vaccinating all boys with the human papillomavirus shot may be less cost-effective than for girls, Bloomberg reports. The improvements in quality and length of life aren't as marked in boys as in girls, the study found, and its authors recommended that health officials focus on vaccinating girls against HPV. |






